Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17523979 | 1.00 | LMNA (0.41) | LMNAGNAO1GNAI3GNAI1ALDH1A1 | |
| SCHEMBL17523885 | 0.98 | LMNA (0.38) | LMNAGNAO1GNAI3GNAI1ALDH1A1 | |
| SCHEMBL17523886 | 0.98 | LMNA (0.38) | LMNAGNAO1GNAI3GNAI1ALDH1A1 | |
| SCHEMBL15183540 | 0.94 | LMNA (0.35) | LMNAALDH1A1KDM4EUSP2 | |
| SCHEMBL15183543 | 0.94 | LMNA (0.35) | LMNAALDH1A1KDM4EUSP2 | |
| SCHEMBL17523967 | 0.90 | PAOX (0.41) | LMNAGNAO1GNAI3GNAI1ALDH1A1 | |
| SCHEMBL17523968 | 0.90 | PAOX (0.41) | LMNAGNAO1GNAI3GNAI1ALDH1A1 | |
| SCHEMBL17524195 | 0.88 | GNAO1 (0.34) | LMNAGNAO1GNAI3GNAI1ALDH1A1 | |
| SCHEMBL17523903 | 0.88 | CHRM4 (0.39) | LMNAALDH1A1KDM4EUSP2PAOX | |
| SCHEMBL17524196 | 0.88 | GNAO1 (0.34) | LMNAGNAO1GNAI3GNAI1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | LMNA 3497/4885GNAO1 4461/4885GNAI3 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.